星空体育官方入口网站网址大全-登录入口官网

#CD137#

7篇内容 | 945人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720636, encodeId=13691e206362b, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, objectType=article, longId=220377, objectId=c40c2203e71e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c40c2203e71e, replyNumber=0, likeNumber=63, createdTime=2022-07-19, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40c2203e71e, moduleTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c40c2203e71e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720637, encodeId=b8f21e2063779, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, objectType=article, longId=726917, objectId=8018e269177f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8018e269177f, replyNumber=0, likeNumber=67, createdTime=2022-12-01, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8018e269177f, moduleTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8018e269177f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720635, encodeId=ebd51e2063511, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, objectType=article, longId=212351, objectId=4525212351b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4525212351b7, replyNumber=0, likeNumber=59, createdTime=2022-02-25, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4525212351b7, moduleTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4525212351b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720634, encodeId=03fc1e2063402, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, objectType=article, longId=185937, objectId=58ff18593e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ff18593e64, replyNumber=0, likeNumber=63, createdTime=2020-09-21, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ff18593e64, moduleTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=58ff18593e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720633, encodeId=48461e2063376, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关, objectType=article, longId=179256, objectId=e0431e9256e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0431e9256e4, replyNumber=0, likeNumber=59, createdTime=2020-03-29, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0431e9256e4, moduleTitle=Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e0431e9256e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720632, encodeId=933e1e2063289, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮, objectType=article, longId=165248, objectId=d2f816524853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2f816524853, replyNumber=0, likeNumber=52, createdTime=2020-02-02, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2f816524853, moduleTitle=Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d2f816524853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720631, encodeId=91271e206317b, content=<a href='/topic/show?id=392442664d' target=_blank style='color:#2F92EE;'>#CD137#</a>, objectTitle=Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展, objectType=article, longId=148521, objectId=7ce6148521ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce6148521ff, replyNumber=0, likeNumber=50, createdTime=2018-09-27, rootId=0, userName=cqlidoudou, userId=644432894735, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce6148521ff, moduleTitle=Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7ce6148521ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD137

2020-05-29

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

Nature Communications：PD-1/CD137双抗效果优异，安全性良好

2022-07-19

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

肿瘤免疫明星靶点：靶向CD137的双抗策略

2022-12-01

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果

2022-02-25

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401

2020-09-21

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关

2020-03-29

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮

2020-02-02

cqlidoudou (审核中...)

前往app查看评论内容

#CD137#

Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展

2018-09-27

科室
- - 订阅+
  - 更多科室
工具
服务